Ailish Hanly, MD
Assistant ProfessorCards
About
Research
Publications
2026
Ostraceous psoriasis in end-stage renal disease: A delayed phenotype switch from dupilumab treated with guselkumab
Craver A, McKenzie P, Hanly A, Vesely M. Ostraceous psoriasis in end-stage renal disease: A delayed phenotype switch from dupilumab treated with guselkumab. JAAD Case Reports 2026, 74: 14-17. PMID: 42381818, PMCID: PMC13316689, DOI: 10.1016/j.jdcr.2026.05.049.Peer-Reviewed Original ResearchThe Histopathological Features of Secondary Syphilis: A Case Series
Hanly A, Panse G, Myung P, Ko C. The Histopathological Features of Secondary Syphilis: A Case Series. Journal Of Cutaneous Pathology 2026, 53: 724-730. PMID: 41948836, DOI: 10.1111/cup.70113.Peer-Reviewed Original ResearchCase of secondary syphilisSecondary syphilisHistopathological featuresPlasma cellsVacuolar interface changesFeatures of secondary syphilisDermal inflammatory cellsH&E-stained slidesSpectrum of inflammatory diseasesProminent inflammationClinicopathological presentationLichenoid inflammationDermatopathology databaseCase seriesLichenoid infiltrateDetection of spirochetesInflammatory cellsInflammatory diseasesReaction patternsSyphilisFlattened epidermisNormal epidermisSerological studiesImmunohistochemistryPatientsUnusual Aggregates of Eosinophilic Proteinaceous Material in the Eccrine Unit of a Patient With Hypohidrosis
Hanly A, Cowper S, Rivera A, Zubek A. Unusual Aggregates of Eosinophilic Proteinaceous Material in the Eccrine Unit of a Patient With Hypohidrosis. Journal Of Cutaneous Pathology 2026, 53: 481-484. PMID: 41651553, DOI: 10.1111/cup.70069.Peer-Reviewed Original Research
2025
Structural Insights: What Makes Some PDE4 Inhibitors More Effective in Inflammatory Dermatoses.
Issa N, Wang J, Hanly A, Ho M, Obagi S, Damiani G, Del Rosso J, Kang Y, Bunick C. Structural Insights: What Makes Some PDE4 Inhibitors More Effective in Inflammatory Dermatoses. The Journal Of Clinical And Aesthetic Dermatology 2025, 18: 18-21. PMID: 40778010, PMCID: PMC12327561.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAtypical bullous systemic lupus erythematosus with features of linear IgA bullous dermatosis
Jiang R, Zhou A, Ko C, Girardi M, Hanly A, Xie C, Preda-Naumescu A, Gehlhausen J, Tomayko M. Atypical bullous systemic lupus erythematosus with features of linear IgA bullous dermatosis. JAAD Case Reports 2025, 58: 74-76. PMID: 40129457, PMCID: PMC11930652, DOI: 10.1016/j.jdcr.2024.12.040.Peer-Reviewed Original Research
2024
Spiny Keratoderma: Clinical and Histopathological Findings in a Series of 3 Cases
Hanly A, Turner N, Ko C, Panse G. Spiny Keratoderma: Clinical and Histopathological Findings in a Series of 3 Cases. American Journal Of Dermatopathology 2024, 46: 439-442. PMID: 38574081, DOI: 10.1097/dad.0000000000002705.Peer-Reviewed Original ResearchThe CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma
Wu M, Hanly A, Gibson F, Fisher R, Rogers S, Park K, Zuger A, Kuang K, Kalin J, Nocco S, Cole M, Xiao A, Agus F, Labadorf A, Beck S, Collard M, Cole P, Alani R. The CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma. Journal Of Clinical Investigation 2024, 134: e171063. PMID: 38300709, PMCID: PMC10940100, DOI: 10.1172/jci171063.Peer-Reviewed Original ResearchConceptsAssociated with inhibitionBRAFi therapyMelanoma phenotype plasticityResistance to MAPK inhibitorsTreatment of melanoma cellsGlobal assessmentBRAF-mutant melanomaP38 MAPK inhibitor BIRBBRAFi-resistant melanomasInhibition of p38 MAPK activityDual-specificity phosphataseRepressor complexNonmutational eventsP38 MAPK activationTargeting epigenetic mechanismsTherapy resistanceTargeted therapyTherapeutic resistancePhenotypic plasticityMelanoma phenotypeMelanomaMelanoma cellsTranscription factorsPhenotypic reprogrammingTherapy
2023
Prurigo Nodularis: Moving Forward.
Hanly A, Watsky K. Prurigo Nodularis: Moving Forward. Cutis 2023, 112: 262-263. PMID: 38290066, DOI: 10.12788/cutis.0903.Peer-Reviewed Original ResearchResults of a National Survey on the Definition of Surgical Site Infections After Mohs Micrographic Surgery
Hanly A, Daniel V, Mahmoud B. Results of a National Survey on the Definition of Surgical Site Infections After Mohs Micrographic Surgery. Dermatologic Surgery 2023, 49: 641-644. PMID: 37382378, DOI: 10.1097/dss.0000000000003817.Peer-Reviewed Original ResearchConceptsMohs micrographic surgerySurgical site infectionMohs surgeonsMicrographic surgerySite infectionSurgical siteDefinitions of surgical site infectionDevelopment of standardized definitionsElectronic surveySurgeonsInfectionSurgeryInfection rateStandard definitionWeb-based surveyMOHPainResearch settingsErythemaStaphylococciNational surveyConsensusEpigenetics and cutaneous neoplasms: from mechanism to therapy
Gibson F, Hanly A, Fisher R, Wyant W, Wu M, Collard M, Alani R. Epigenetics and cutaneous neoplasms: from mechanism to therapy. Epigenomics 2023, 15: 167-187. PMID: 37020393, DOI: 10.2217/epi-2023-0016.Peer-Reviewed Original ResearchConceptsCell carcinomaGene expression patternsResistance to cancer therapyHistone modificationsRNA modificationsDisease-associated alterationsDNA methylationGenomic DNAT-cell lymphomaSquamous cell carcinomaEpigenetic modificationsBasal cell carcinomaExpression patternsEpigenetic dysregulationNeoplastic disease progressionCutaneous malignanciesMalignant melanomaT cellsCutaneous neoplasmsTherapeutic resistanceDisease progressionEpigeneticsCancer therapyTherapeutic strategiesDNA